anti-BCMA CAR T-cell therapy (Sichuan University)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-BCMA CAR T-cell therapy (Sichuan University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocytes stimulantsImmunostimulantsTumor necrosis factor ligand superfamily member 13 modulators

TargetsTumor necrosis factor ligand superfamily member 13

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesSichuan University

China Registration ClassN/A

Develop Information

Active CompaniesSichuan University

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A